American Century Companies Inc. Boosts Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

American Century Companies Inc. grew its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 35.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 27,892 shares of the biotechnology company’s stock after purchasing an additional 7,287 shares during the quarter. American Century Companies Inc. owned approximately 0.13% of Enanta Pharmaceuticals worth $362,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Quest Partners LLC lifted its stake in shares of Enanta Pharmaceuticals by 511.2% during the 2nd quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 9,692 shares during the period. Rhumbline Advisers increased its holdings in shares of Enanta Pharmaceuticals by 4.7% during the 2nd quarter. Rhumbline Advisers now owns 34,566 shares of the biotechnology company’s stock worth $448,000 after buying an additional 1,548 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in shares of Enanta Pharmaceuticals during the 2nd quarter worth $35,000. Bank of New York Mellon Corp increased its holdings in shares of Enanta Pharmaceuticals by 13.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 73,841 shares of the biotechnology company’s stock worth $958,000 after buying an additional 8,645 shares during the last quarter. Finally, Farallon Capital Management LLC increased its holdings in shares of Enanta Pharmaceuticals by 3.5% during the 1st quarter. Farallon Capital Management LLC now owns 2,095,000 shares of the biotechnology company’s stock worth $36,579,000 after buying an additional 70,000 shares during the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Insiders Place Their Bets

In other Enanta Pharmaceuticals news, insider Scott T. Rottinghaus sold 5,375 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $17.08, for a total value of $91,805.00. Following the transaction, the insider now owns 21,717 shares in the company, valued at $370,926.36. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other Enanta Pharmaceuticals news, insider Scott T. Rottinghaus sold 4,299 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $15.07, for a total transaction of $64,785.93. Following the transaction, the insider now directly owns 23,988 shares in the company, valued at approximately $361,499.16. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Scott T. Rottinghaus sold 5,375 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $17.08, for a total transaction of $91,805.00. Following the transaction, the insider now owns 21,717 shares in the company, valued at $370,926.36. The disclosure for this sale can be found here. 13.64% of the stock is currently owned by company insiders.

Enanta Pharmaceuticals Price Performance

NASDAQ ENTA opened at $11.19 on Friday. Enanta Pharmaceuticals, Inc. has a 12 month low of $8.08 and a 12 month high of $17.80. The firm has a market capitalization of $236.99 million, a PE ratio of -1.79 and a beta of 0.59. The company’s 50 day simple moving average is $12.38 and its 200 day simple moving average is $13.36.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.07) EPS for the quarter, beating analysts’ consensus estimates of ($1.43) by $0.36. Enanta Pharmaceuticals had a negative net margin of 160.27% and a negative return on equity of 63.75%. The business had revenue of $17.97 million for the quarter, compared to analyst estimates of $17.44 million. During the same quarter last year, the business earned ($1.27) earnings per share. The business’s revenue for the quarter was down 4.9% on a year-over-year basis. Sell-side analysts anticipate that Enanta Pharmaceuticals, Inc. will post -5.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently issued reports on ENTA. HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, August 6th. Evercore ISI raised shares of Enanta Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, August 6th. JMP Securities reissued a “market outperform” rating and issued a $22.00 target price on shares of Enanta Pharmaceuticals in a report on Friday, September 27th. Finally, JPMorgan Chase & Co. cut their target price on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating on the stock in a report on Tuesday, August 6th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.00.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.